Comparative Pharmacology
Head-to-head clinical analysis: CATAPRES versus CATAPRES TTS 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAPRES versus CATAPRES TTS 3.
CATAPRES vs CATAPRES-TTS-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance and lowered blood pressure.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Oral: 0.1 mg twice daily initially, titrate to 0.2-0.6 mg/day in divided doses; maximum 2.4 mg/day. Transdermal: 0.1 mg/24 hours patch applied every 7 days, titrate to 0.2-0.3 mg/24 hours.
Transdermal patch: 0.3 mg/day applied once every 7 days; initial dose 0.1 mg/day, titrate weekly by 0.1 mg/day increments to desired response.
None Documented
None Documented
Terminal elimination half-life: 12-16 hours in normal renal function; prolonged to 48-96 hours in severe renal impairment. Use with caution in CKD.
Terminal elimination half-life is 12-16 hours after oral administration; with transdermal delivery, the effective half-life is prolonged to 20-40 hours due to continued absorption from the skin depot. In renal impairment, half-life may extend to 40 hours or longer.
Renal: ~65% (40-50% unchanged; 20-25% as metabolites). Biliary/fecal: ~35% (conjugated metabolites).
Approximately 40-60% of the absorbed dose is excreted unchanged in urine. About 20-30% is eliminated as metabolites via bile and feces. Renal clearance accounts for 50-60% of total clearance.
Category C
Category C
Central Alpha-Agonist
Central Alpha-Agonist